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T he expansion of the U.S. Medicare program through the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) began an important new chapter in national health policy. 1 MMA provided not only an outpatient prescription drug benefit but also new medication therapy management (MTM) programs for eligible beneficiaries. MTM services were conceived so that therapeutic outcomes would be optimized through improved medication use and through reduced risk of adverse events. 1 During approximately the same period of time, state-based Medicaid programs and selfinsured employer groups used similar approaches and focused on improving medication therapy outcomes.
These goals of MTM and similar programs are consistent with, and central to, modern pharmacy practice concepts. 2 In light of the strong link between MTM services and modern pharmacy practice, and the specific naming of pharmacists as providers of MTM services for Medicare beneficiaries, 1 the pharmacy profession adopted the terminology and assumed leadership for planning and implementing MTM services for all patients. For example, pharmacy organizations provided leadership for developing business and payment models, 3 consensus definitions, 4 core element frameworks, 5, 6 and procedural terminology codes for billing third-party payers, [7] [8] [9] [10] therefore enabling the profession to offer a consistent approach for providing MTM services to patients qualifying for and wishing to receive them.
A consensus definition for MTM was achieved among 11 national pharmacy organizations in July 2004, 4 and core elements for providing MTM services were established in 2005 to "maximize both effectiveness and efficiency of MTM service delivery across pharmacy settings in an effort to improve continuity of care and patient outcomes." 5, 6 The published definition has served as a foundation for the pharmacy profession and was our focus of inquiry. Thus, for our study, MTM was defined as "a distinct group of services that optimize therapeutic outcomes for individual patients. MTM services are independent of, but can occur in conjunction with, the provision of a medication product. MTM encompasses a broad range of professional activities and responsibilities within the licensed pharmacist's or other qualified health care provider's scope of practice. MTM services encompass those services being provided either via face-to-face contact or telephonically by a pharmacist or other qualified health care professional, but do not include mailings to a patient." [2] [3] [4] [5] [6] For clarification, we note that some MTM services provided by companies contracted by the Centers for Medicare & Medicaid Services under Medicare Part D are not considered MTM by this definition and, thus, are not investigated in this study (most notably, e-mail/Internet-based information or educational information mailed to patients and/or practitioners).
Recent reports in the literature describe how MTM services have been implemented in the United States. [11] [12] [13] [14] To date, the literature contains information about the initial planning and implementing of MTM services. However, we are not aware of any published reports regarding the value of MTM services to providers and payers of these services. Such information would be useful for future planning and for implementation decisions regarding the use of pharmacist-provided MTM services.
Objectives
To add to what is known about the initial implementation phases of these services and related programs, the purpose of this study was to conduct an environmental scan of pharmacistprovided MTM services during 2007 in which the opinions of payers for these services and providers of these services would
At a Glance
Synopsis: A total of 687 individuals who were likely to be involved directly with pharmacist-provided medication therapy management (MTM) services or to be responsible for individuals who provided MTM services completed a self-administered online survey assessing implementation and monitoring of MTM during 2007. Based on a consensus definition provided to these potential MTM service providers, 65% indicated that they provided, 27% indicated that they did not provide, and 8% indicated that they did not know whether they provided MTM. Of the 65% of respondents reporting that they provided MTM services, 47% indicated that they were contracted with programs to provide MTM services. Methods for implementing, quantifying the costs and benefits of, and assessing the value of providing MTM services varied considerably among respondents. Barriers to providing MTM included lack of pharmacist time, insufficient staffing, devoting large amounts of time to dispensing activities, and difficulties in billing for MTM. reseArch MTM PROvIDER PERSPECTIvES be collected and summarized regarding how service implementation is being monitored and value is being assessed. We sought to answer from both payer and provider perspectives these specific questions: ■ What implementation strategies were used for providing MTM services to patients/clients? ■ What specific measures, if any, were used to quantify the costs and benefits of MTM? ■ How was the value of MTM services tracked during 2007? ■ What were the barriers to offering MTM services to patients/ clients?
We used the professionwide consensus definition of MTM [4] [5] [6] for our study so that the findings could be applied to a diverse array of patient populations and would not be limited to patients who are eligible for MTM services under the Medicare Part D program. Furthermore, we chose to focus specifically on pharmacist-provided MTM for several reasons. First, pharmacists were the health professional group specifically named as MTM providers in MMA. 1 Second, by using this focus, we sought to add to reports in the pharmacy literature on pharmacist-provided MTM. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Finally, this focus would allow the sponsor of the project (American Pharmacists Association [APhA] ) to use the findings in making decisions about how to serve its members and the pharmacy profession. The purpose of the remainder of this article is to report findings from the provider perspective. An article in the July/August issue of JAPhA will describe payer perspectives for the study questions; it is available at www.japha. org in advance of print publication.
Methods study sample: Providers
The provider sample was selected in a nonrandom purposive manner. The goal was to select the sample members based on those who either were likely to have had direct involvement with pharmacist-provided MTM services as part of their practice or had responsibility for individuals who provided such services. Individuals were identified from APhA databases and included both APhA members and nonmembers involved in (1) pharmacy residency programs, (2) executive pharmacy management, (3) clinical coordinator positions, (4) MTM certificate training programs, (5) MTM advisory panels, (6) MTM best-practices programs, or (7) general practice settings. After removing any individuals from this list who had requested not to receive e-mails from APhA or who had an undeliverable e-mail address, a total of 6,873 individuals were included in the provider sample. Institutional review for treatment of human subjects was conducted internally by APhA. The Association also conducted data collection and served as final repository for the data.
Data collection
Data were collected via a self-administered online survey. FormSite services were used for creating and administering the survey (www.formsite.com). FormSite is a self-service tool that enables the creation of HTML forms using a Web browser. Survey forms for this study were created using an Internet connection and stored on secure FormSite servers located in Chicago. Form results were stored on these servers and were available for review by research personnel in secure format 24 hours per day. Respondent names were not identified in the data files. The invitation to participate in the survey was sent to sample members via e-mail with an open participation period from November 14, 2007, through December 3, 2007. Questions for the survey were developed by a geographically diverse expert advisory panel convened by APhA staff via a series of conference calls during fall 2007. The resulting survey form included questions regarding (1) provision of MTM services, (2) patient participation in MTM services, (3) investment into MTM services, (4) value of MTM services, (5) payment for MTM services, (6) future considerations for providing MTM services, and (7) respondent background information. A copy of the survey form is available upon request from the corresponding author.
Data analysis
Data files from the FormSite data repository were converted to SPSS version 16.0 for analysis (www.spss.com). Descriptive statistics were used for summarizing responses, and openended responses were selected to provide further insight for answering the research questions. To learn more about several responses, we conducted subanalyses in which we investigated differences in response patterns among categories of work position and practice setting. Because we conducted these multiple comparisons in a post hoc fashion, and in light of relatively large standard deviations for the variables tested, we set the level of statistical significance at P < 0.01.
results
Of the 6,873 providers who presumably received an e-mail invitation to participate in the survey, 687 (10%) responded and were included in the analysis. The respondents had diverse pharmacy-related training backgrounds and were distributed throughout the United States. A summary of job titles and organization classifications for respondents is presented in Table 1 .
For the question, "Do you or your organization provide MTM services as defined in the consensus definition?" 65% reported "yes," 27% "no," and 8% "don't know." The distributions of job titles and organization classifications for respondents who reported "yes" to this question were similar to those summarized in Table 1 . Of respondents who reported that they provided MTM services, 47% reported that they contracted with programs for providing MTM services, while 28% reported that they did not and 26% that they did not know.
Implementation strategies for MTM services
For respondents who indicated that they were implementing MTM services, 50% reported that they actively identified patients as potential candidates for MTM services, 41% reported that they did not, and 9% reported they did not know. Those who did not identify patients themselves relied on health plans, Part D plans, employer groups, referrals from other professionals, patient self-referral, or chance.
Respondents who reportedly identified patients as potential candidates for MTM services typically used multiple strategies within their organizations, including, but not limited to, number of medications taken, specific medications, number of diseases, specific diseases, specific health plan, specific level of drug spend, emergency department or hospital discharges, suspected adverse drug reaction, history of nonadherence, or suspected medication-related problem. When asked to whom they actively marketed MTM services, more than one-half of respondents indicated "no one" or that "they did not know if they did or not" (31% and 20%, respectively). The remaining 49% reported marketing to multiple groups, including, but not limited to, commercial insurance, Medicare supplement plans, Medicare Advantage plans, Medicare stand-alone prescription drug plans, managed care, preferred provider organizations, health indemnity plans, self-insured groups, home care/hospice, longterm care, federal government, and state Medicaid programs. Written comments revealed several themes regarding this topic, as follows: (1) providers used widely varying strategies ranging from marketing to any person who might benefit from their services to marketing only to their own employees who had diabetes, (2) providers planned to expand their marketing efforts in 2008, and (3) marketing activities often were coordinated only at the corporate office level with none occurring at the individual pharmacy level.
For providers who reported billing for MTM services, multiple billing methods typically were used at each site. The most commonly used methods were Internet (proprietary Web portal) and the pharmacy's own computer system. However, paper (claim form/invoice) and fax methods also were used.
When asked about what billing format(s) their organizations used for MTM claims submission (e.g., 1500 form, X12 837 electronic, National Council for Prescription Drug Programs), 57% reported they did not know.
Based on 83 usable responses, the most commonly reported methods on which to base payment for MTM services are summarized in Table 2 . The most common response was time only (24%), followed by time/type of MTM service/level of complexity (23%). Time was mentioned alone or in combination with other methods by 74% of respondents. Type of MTM service was mentioned alone or in combination with other methods by 61% of respondents. Level of complexity was mentioned alone or in combination with other methods by 34% of respondents.
When those who used a fee-for-service basis for billing were asked about their average rate, almost all respondents reported that they did not know. For the 19 respondents who provided an answer, the fees ranged from $1 to $3 per minute ($60-$180/ hour).
Measures used to quantify costs and benefits of MTM
In terms of learning about measures used for quantifying costs, 69% of respondents reported that they incurred costs for offering MTM services in their organization, while 18% reported that they incurred no costs and 13% that they did not know. Of those reporting that they incurred costs, most were related to staff training or addition of staff. To a lesser extent, costs for remodeling facilities, installing technology, or purchasing equipment/supplies were reported. Only 4 of 289 respondents who answered a question requesting specific average dollar amount invested for each individual location where MTM services were provided were able to report an amount. All others (285 of 289) reported "don't know." Based on written comments, reasons for not knowing this information were associated with (1) viewing reseArch MTM PROvIDER PERSPECTIvES MTM as something already being done as part of routine practice using existing staff, (2) not having the resources for quantifying costs, (3) knowing only some cost information for their organization, and (4) reporting that the primary costs for MTM services were for personnel.
Regarding measures used for quantifying benefits, respondents were asked to report any quality indicators that were improved from provision of MTM services and to respond to a series of questions about (1) revenue generated from MTM, (2) increased prescription volume, (3) increased prescription sales, (4) increased patient traffic, and (5) any other measures of value used. The results revealed that 70% of the respondents did not know of any quality indicators that were improved from MTM services. Of the remaining 30% who did report indicators, two-thirds (20% of all respondents) indicated quality indicators of a general nature, such as patient satisfaction, quality, professional satisfaction, adherence, and improved interactions with others. One-third of those reporting indicators (10% of all respondents) indicated specific quality indicators such as glycosylated hemoglobin, blood pressure, lipid profile, weight control, absenteeism, length of stay in health facilities, cost of medications, smoking cessation, overall health care costs, number of medications, dosing adjustment, and adverse drug reactions When asked to report the monthly dollar revenue generated by MTM, 97% of respondents indicated that they did not know. Of the eight respondents who provided an answer, the amounts ranged from −$1,500 to $1,500 per month per location. Regarding percentage increase in prescription volume, only 2% of the responders (n = 7) provided an answer other than "don't know." Of the seven who answered, five reported none/unimportant, with one person reporting 0% to 2% and the other reporting 2% to 3%. Only four respondents chose to answer the question regarding percentage increase in prescription sales. Of these, three reported no increase and one reported a decrease in prescription sales. A similar response was given for a question about the percent increase in patient traffic: two of the four responders reported no increase, and the other two reported "<5%" and "increased."
Providers were also asked to report any other measures used to quantify benefits. Two-thirds (67%) of respondents provided specific answers that included cost savings, cost avoidance, number of drug-related problems identified, number of interventions provided, decreased inappropriate therapy, patient satisfaction scores, decreased hospitalizations, pain management, diabetes management, profit increase of 4%, wait times in pharmacy, prescription drug cost per member per month, data library generation, and nurse, physician, and/or patient education.
One-third (33%) of the respondents to this question did not provide specific answers but, instead, commented that (1) providers may consider MTM to be part of the care they have given to all of their patients and do not quantify benefits, (2) they do not have the resources or expertise for quantifying benefits from MTM services, or (3) the services are too new for them to detect any quantifiable impact at this point in time. These comments were evenly distributed (11% for each answer).
Assessing value of MTM services during 2007
To help learn how the value of MTM services was assessed during 2007, respondents were asked to rate, using a Likerttype scale (1, very unimportant, to 5, very important) six criteria in reference to their importance in providing value to their organization as a result of MTM services. Those who reported that they were providing MTM services were asked about actual value, and those who reported that they were not, or did not know whether they were, providing MTM services were asked about the potential value to their organization. Results for this question are presented in Table 3 and show that the most important criteria were (1) increased professional satisfaction (overall mean 3.7), (2) increased quality of care (3.7), and (3) increased patient satisfaction (3.7). Other criteria were rated as being less important (revenue generated from MTM services, increased patient traffic, increased prescription volume, and increased prescription sales). Table 3 also reveals that the pattern of responses was significantly different for those who reported providing MTM services compared with those who did not. Those providing MTM services typically reported lower scores (actual value scores) than other responders (potential value scores) (Table 3) .
To learn more about how the value of MTM services was assessed during 2007, we conducted a subanalysis in which we investigated differences in response patterns among categories of work position (management or staff) and practice setting (large chain of >10 units, independent/small chain, or inpatient settings) while controlling for provision of MTM services (yes or no). Of the 536 respondents shown in Table 3 , we were able to categorize 457 of them into these post hoc categories for analysis. The results showed that work position did not significantly affect the pattern of responses for any of the variables in Table 3 . However, practice setting significantly affected three of the six variables, namely, increased patient traffic, increased prescription volume, and increased prescription sales. For each of these three variables, respondents categorized as working in large chain settings reported these as more important in providing value to their organization than those working in independent/ small chain settings, who, in turn, rated the variables as more important than respondents working in inpatient settings (P < 0.01 for each comparison).
Asking those who were offering MTM services how important several factors were in their organization's decision to begin providing MTM services was another way we gained insight into how providers assessed the value of MTM services to their organization. Table 4 summarizes the results for this question and shows that the most important factors were (1) patient needs, (2) responsibility as a health provider, (3) recognized a need to improve health care quality, (4) contribution to health care team, and (5) professional satisfaction. Of lesser importance were reducing health care system costs, primary business mission, reducing health insurer costs, provider needs, need for other revenue sources, competitive pressure, and decreased reseArch MTM PROvIDER PERSPECTIvES prescription volume.
To learn more about how important these factors were in an organization's decision to begin providing MTM services, we conducted a subanalysis in which we investigated differences in response patterns among categories of work position (management or staff) and practice setting (large chain of >10 units, independent/small chain, or inpatient settings). Of the 381 respondents in Table 4 , we were able to categorize 313 of them into these post hoc categories for analysis. The results showed that practice setting exerted a significant main effect on 4 of the 12 variables and that the interaction term (work position × practice setting) exerted a significant effect on one of the variables (P < 0.01). Regarding the significant main effects of practice setting, the results showed that large chain settings rated the variable "patient needs" as less important than the other two practice setting categories. For the variable, "need for other revenue sources," both large chain and independent/ small chain settings rated this variable as more important compared with respondents categorized as working for "inpatient settings." Respondents in large chain settings rated "competitive pressure" as more important compared with the other two practice settings. Finally, "decreased prescription volume" was rated as most important by large chain settings, followed by independent/small chain and inpatient settings.
The interaction term (work position × practice setting) significantly affected the variable "recognized a need to improve health care quality" (P < 0.01). The interaction occurred because those in staff positions rated this as more important than those in management positions for the independent pharmacy practice setting (mean 4.8 and 4.7, respectively). For the other two practice settings, the relationship was reversed; those in management positions rated the variable as more important (4.8 for large chains and 4.9 or inpatient settings) compared with those in staff positions (4.4 for large chains and 4.8 for inpatient settings).
Finally, we investigated value in terms of return on investment (ROI). Of those who reported that they were contracted with programs for MTM services provision, 35% reported that the contracts provided a positive ROI, 31% reported that they did not provide a positive return, and 34% reported that they did not know.
Barriers to providing MTM services
Another goal of our study was to gain insight about factors that may have prevented providers from offering MTM services to their patients. To do this, we asked respondents who reported that they were not providing MTM to report how important (1, very unimportant, to 5, very important) 15 factors were in preventing them from offering MTM. Table 5 provides a summary of the results and shows that the most important factors were (1) pharmacists have inadequate time, (2) staffing levels insufficient, (3) dispensing activities too heavy, and (4) billing for MTM is difficult. Respondents also were asked to write in any comments they had about this section in the survey, and 41 respondents did so. Most comments revealed that respondents would like to be more actively engaged in patient care services such as MTM but that they viewed their current work environment as not being conducive to providing MTM. Of note, respondents who were offering MTM services were not asked these questions.
To learn more about these barriers to offering MTM services (for those not offering them), we conducted a subanalysis in which we investigated differences in response patterns among categories of work position (management or staff) and practice setting (large chain of >10 units, independent/small chain, or inpatient settings). Of the 186 respondents in Table  5 , we were able to use 171 of them for the subanalysis. The results showed that work position did not significantly affect the pattern of responses for any of the variables in Table 5 and that practice setting affected only 2 of the 15 variables. For the variables "inadequate training/experience to provide MTM" and "inadequate space available for providing MTM," respondents categorized as working in large chain settings reported these as more significant in preventing them from providing MTM compared with respondents in the other two practice setting categories (P < 0.01).
Discussion
The results showed that 65% of the respondents to this survey were involved in MTM provision as defined in the consensus definition. Based on the nonrandom sampling method we used, we suspect that this proportion is higher than that which would be found for the overall population of providers in the United States. Of the respondents who were involved in providing MTM services, 47% reported that they were contracted with programs for providing MTM services. Such contracts reportedly provided a positive ROI for 35% of these respondents, while 31% reported that they did not provide a positive ROI and 34% that they did not know.
Findings related to implementation strategies for MTM services revealed wide variation in what was reported. Some responses revealed a "passive" approach to implementation, in which the services may have been provided to patients as part of normal care but that little or nothing was done to promote, develop, or monitor MTM service offerings. Other responses revealed an approach we describe as one of "pursuit and exploration." In this implementation strategy, multiple strategies and ideas were used concurrently. Finally, some responses revealed an "unsure" approach to implementation in which the respondent deferred to others for decisions or reported that they did not have access to information to respond to our questions.
Providers typically did not use specific measures to quantify the costs and benefits of MTM. As of 2007, providers did not use systematic methods for assessing value from providing MTM services to their patients. Rather, they associated value with provision of such services as being part of their professional role in the health care system and society.
The most common barriers to offering MTM services (for respondents not currently offering them) were lack of time, insufficient staffing, heavy medication dispensing responsibilities, and difficulty in billing for MTM. Most of these barriers relate to staffing and workflow within the pharmacy practice. These are operational issues that need attention whenever new services are brought into practice.
With no apparent business case being reported for MTM services, providers' reluctance or unwillingness to allocate resources to provide them is understandable. Financial performance of new pharmacy services needs to be tracked for the services to be evaluated, monitored, and sustained. In our view, MTM services are relatively new and adoption of business models for provision of such services may be slow. 15, 16 Unlike the adoption of a close substitute, such as a new type of seed for planting in agriculture, MTM services differ substantially from traditional pharmacist work activities. Using the seed example from agriculture, a new hybrid seed can be adopted quickly In contrast, the diffusion of an emergent service offering such as MTM services involves new patient groups to be identified and recruited, new methods of service provision to be adopted, new patient care procedures to be used, new documentation and billing systems to be developed, and new ways for distributing the service to be established compared with traditional pharmacist work activities such as medication product dispensing and associated consultation. In addition, metrics for monitoring ROI are different and difficult to compare between MTM services and medication dispensing services. Such disparity may be making it difficult for providers to assess the opportunity costs of maintaining the status quo for the short term versus transitioning into MTM services provision. The transition may be especially slow if current business models are sufficiently profitable and a transition to offering MTM services is viewed as uncertain and risky.
Our finding that the primary reasons for providing MTM services were "meeting patient needs" and "fulfilling one's responsibility as a health provider" supports the notion that the transition into MTM services provision is not primarily for financial gain but, rather, for professional fulfillment and satisfaction as a patient care provider. These findings may be reflecting pharmacists' current motivation for providing MTM as one of meeting patient needs because models for measuring or justifying success in business terms are not widely available.
Concurrent developments may help speed the diffusion of MTM services as a standard of patient care and the advancement of a more systematic and sophisticated understanding of metrics for assessing ROI for such services. These developments include the efforts already completed within the pharmacy profession regarding business and payment models for MTM, 3 consensus definitions, 4 core element frameworks, 5,6 current procedural terminology codes for billing third-party payers, [7] [8] [9] [10] and documentation systems (www.pharmacist.com/AM/Template.cfm?Section=Documentation_and_Billing). In our opinion, these resources serve as a solid foundation for provision of MTM services that are effective, efficient, consistent, applicable across pharmacy practice settings, widely accepted, and conducive for continuity of patient care within the health care system. We suggest that building on these initial efforts through continued development, broad dissemination, and objective evaluation would establish an even stronger foundation for modern pharmacy practice.
Other emerging efforts may help speed the diffusion of MTM services and create incentives for providers to develop more systematic and sophisticated metrics for evaluating these services. For example, PQA, a pharmacy quality alliance (www.
pqaalliance.org), is working to "improve health care quality and patient safety through a collaborative process in which key stakeholders agree on a strategy for measuring performance at the pharmacy and pharmacist levels; collecting data in the least burdensome way; and reporting meaningful information to consumers, pharmacists, employers, health insurance plans, and other health care decision makers to help make informed choices, improve outcomes and stimulate the development of new payment models" (emphasis ours).
Another example of a concurrent effort is the National Committee for Quality Assurance (NCQA; http://web.ncqa.org), which develops "quality standards and performance measures for a broad range of health care entities. These measures and standards are the tools that organizations and individuals can use to identify opportunities for improvement. The annual reporting of performance against such measures has become a focal point for the media, consumers, and health plans, which use these results to set their improvement agendas for the following year."
External metrics and standards generated by organizations such as PQA or NCQA can serve as the basis for a business case for services such as MTM so that allocation of planned and defined resources can be approved and applied by organizations. In addition, financial performance evaluation for new services such as MTM could mirror performance standards generated by national consensus groups such as PQA and NCQA. Through the generation of consensus standards and metrics, services such as MTM could be evaluated, monitored, and sustained from an ROI perspective.
We suggest that professional pharmacy associations can play active roles for research, demonstration projects, training, professional resources, and advocacy as evidentiary and analytical standards are established for MTM services and programs. In addition, our findings show that individual practitioners provided MTM services for professional fulfillment and satisfaction as patient care providers rather than for financial gain. We propose that individual providers should actively try to persuade their employers/organizations that investment in MTM services has merit and that active approaches to implementation and monitoring would be in the organization's self-interest. Furthermore, information gained from monitoring MTM financial and health outcomes would be useful for organizations when negotiating contracts with payer programs. Individual practitioners also could express an interest in becoming more involved in demonstrating successful business models to promote MTM service delivery. In the health care domain, tensions commonly develop between direct patient practice models and financial considerations or limitations. Individual practitioners may feel that they do not have decision-making authority within their practice. However, we suggest that professional enthusiasm and advocacy for emergent services such as pharmacist-provided MTM can help inform and persuade organizational decision makers to take more active approaches to implementing and evaluating such services. In addition, such activities could increase the likelihood that individual practitioners would be included in decision making and could help ensure successful integration of MTM into practice.
Limitations
The findings of this study should be interpreted in light of the study's limitations. First, we applied a pharmacy profession consensus definition for MTM. Other definitions or perspectives for MTM services could lead to different findings. Second, we used a purposive sampling technique in which we sought to survey individuals who either were likely to have had direct involvement with providing MTM services or had responsibility for individuals who provided MTM services. This approach allowed for "informed opinions" from "engaged key opinion leaders" in our data collection, but the findings cannot be generalized to the overall provider population in the United States. Third, respondents appeared to be able to answer questions that were site specific but less able to answer questions that asked about the characteristics of overall corporations or organizations. Conducting surveys at the corporate level to answer some of the questions posed in our study may be necessary. Finally, the use of an online survey provided both time and cost advantages. However, this survey method suffers from poor response rates. We were willing to accept this limitation because our goal was to gain insights and informed opinions from engaged key opinion leaders. However, the findings cannot be extrapolated to the broader MTM provider population.
conclusion
The results of this study showed that providers varied widely on how they implemented MTM service offerings and typically did not use specific measures to quantify the costs and benefits of MTM. In addition, they did not use systematic methods for assessing value from providing MTM services to their patients. Rather, they associated value with provision of such services as being part of their professional role in the health care system and society. 
